Short Duration Alagebrium Chloride Therapy Prediabetes Does Not Inhibit Progression to Autoimmune Diabetes in an Experimental Model

Short Duration Alagebrium Chloride Therapy Prediabetes Does Not Inhibit Progression to Autoimmune Diabetes in an Experimental Model

Mechanisms by which advanced glycation end products (AGEs) contribute to type 1 diabetes (T1D) pathogenesis are poorly understood. Since life-long pharmacotherapy with alagebrium chloride (ALT) slows progression to experimental T1D, we hypothesized that acute ALT therapy delivered prediabetes, may b...

Full description

Bibliographic Details
Main Authors: Danielle J. Borg, Pouya Faridi, Kai Lin Giam, Peta Reeves, Amelia K. Fotheringham, Domenica A. McCarthy, Sherman Leung, Micheal S. Ward, Brooke E. Harcourt, Rochelle Ayala, Jean L. Scheijen, David Briskey, Nadine L. Dudek, Casper G. Schalkwijk, Raymond Steptoe, Anthony W. Purcell, Josephine M. Forbes
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Metabolites
Subjects:
advanced glycation end products
alagebrium chloride
cross-link breaker
immunopeptidome
MIN6N8 cell line
NOD mouse
Online Access:https://www.mdpi.com/2218-1989/11/7/426

Internet

https://www.mdpi.com/2218-1989/11/7/426

Similar Items